Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Screw shorty day most likely
It's always funny - everyone hates apple at 110 but they love it at 130 ..
Wash rinse repeat !
Let's see if my bull theroy holds true
Rip anyone writing puts on this pig
Wiped out huge gains - in one move . No one even had a Chance
The gap up 2 morro should be awesome
Look at em running for cover
A sight for sore eyes today for sure
And the beat rolls on -
$NAVB - nice gain today
Mm's are stop loss hunting
Gap fill around $130 would be awesome
Whoops lol
Wowza - you still holding ?
What's the deal here
Traders will push this higher into the close - appl should out perform spy by a mile next week
All my opinion.
This puppy always makes ya regret bailing..
Sentiment is low - if they surprise with something big could get very interesting fast IMO
Still baffles me with how much money star wars is still racking in
Now comes the "hope" phase of getting money back for anyone that's under water and averaging down ..
This can be a brutal phase as just when you think you bought in for bounce the futures traders kill it again..
Wash rinse repeat - RS
GOOD LUCK TO ALL HOLDING
Come on $DIS take out $105
Navidea Awarded $1.8M Fast Track NIH SBIR Grant for Evaluation of a Manocept™ Agent in Kaposi’s Sarcoma
Source: Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) is announcing the receipt of an initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant providing for up to $1.8 million from the National Cancer Institute (NCI), National Institutes of Health (NIH), to fund preclinical studies examining the safety of intravenous(IV) injection of Tc99m tilmanocept, a Manocept™ platform product, followed by a clinical study providing the initial evaluation of the safety and efficacy of SPECT imaging studies with IV Tc99m tilmanocept to identify and quantify both skin- and organ-associated KS lesions in human patients.
The SBIR grant is awarded in two parts with the potential for total grant money of up to $1.8 million over two and a half years. The first six-month funding segment of $300,000, which has already been awarded, is expected to enable Navidea to secure necessary collaborations and Institutional Review Board (IRB) approvals. The second funding segment could provide for up to an additional $1.5 million to be used to accrue participants, perform the Phase 1/2 study and perform data analyses to confirm the safety and effectiveness of intravenously administered Tc99m tilmanocept.
“We appreciate the recurring support by the NIH which we believe reflects, in part, their confidence in the strength of our clinical development capabilities. This study reinforces our commitment to support the expanded use of Lymphoseek® (technetium Tc99m tilmanocept) injection to help patients afflicted with other solid tumor cancers,” said Michael Tomblyn, M.D., Navidea’s Chief Medical Officer. “Positive outcomes showing that intravenously injected Tc99m tilmanocept localizes specifically and at detectable levels in KS lesions would open the possibility that a Manocept-drug conjugate might be used to target delivery of therapeutics to KS lesions.”
“Building on earlier research showing KS tumor cells abundantly express CD206, the tilmanocept receptor, and successful imaging with subcutaneous injection, we plan to evaluate intravenous administration of this targeted imaging agent to noninvasively locate internal KS lesions, which are currently challenging to identify and monitor,” commented Toby Maurer, M.D., FAAD, Professor of Dermatology at the University of California, San Francisco (UCSF), and Chief of Dermatology at San Francisco General Hospital and Trauma Center, who is co-PI at UCSF with Michael S. McGrath, M.D., PhD. “If successful, future diagnostic and eventually therapeutic developments have the potential to dramatically improve life expectancies and quality of life for patients suffering from Kaposi’s sarcoma.”
About the Preclinical animal studies
Preclinical animal studies and laboratory test development will investigate the feasibility and support clinical protocol development for intravenous administration of Tc99m tilmanocept in human patients with KS and will include method development and validation for dose solution analysis and various pharmacology, pharmacokinetic and toxicology analysis in animals.
About the Phase 1/2 Clinical Study
This study has been designed as a single center, open-label, non-randomized, Phase 1/2 Clinical Study to evaluate intravenous injection of Tc99m tilmanocept into KS patients. The study, using imaging with single-photon emission computed tomography (SPECT) and likely, SPECT/CT, will evaluate the ability of Tc99m tilmanocept to identify KS lesions and bind to CD206 on KS cells and their tumor-associated macrophages (TAMs). Various doses of Tc99m tilmanocept will be evaluated. The study is expected to involve up to 48 patients with HIV- or transplant-associated KS and last 2 years. The goal of the study is to provide evidence evaluating the safety and efficacy as well as optimal dosing and timing of Tc99m tilmanocept as a SPECT imaging agent for KS lesions.
About Kaposi’s Sarcoma
Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph nodes or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body, such as in the lymph nodes (bean-sized collections of immune cells throughout the body), the lungs, or digestive tract. The abnormal cells of KS form purple, red, or brown blotches or tumors on the skin. These affected areas are called lesions. The skin lesions of KS most often appear on the legs or face. AIDS-related KS is the most common type of KS in the United States and develops in people who are infected with HIV, the virus that causes AIDS. KS can also develop in people whose immune systems have been suppressed after an organ transplant and is called transplant-related KS.1
This thing is getting crushed
Weeeee lol
Weekly 59 lotto puts
Good luck to you - these ETN / ETF vehicles have a funny way of teaching people about greed - and it usually comes outta no where and it'll lose 50%
All just my opinion
Citron is shorting NFLX - I missed that news yesterday
Wonder if NFLX can bankrupt that group
Per CNBC the world is ending lol
Short UVXY - prolly the greatest short of this year
I find it hilarious for years they been dreaming for a 10 % pullback - now everyone is setting their hair on fire and jumping off buildings because the world is ending..
Lol
Good luck my friend - IMO VIX will be crushed
Fed won't do a damn thing to hurt this market..
No way Obama will go out on a chit market
Gunna be spectacular to watch this pos plummet with a bunch of suckers holding the bag
Retail chasing this pig.. Big boys will destroy this quickly
$CVC - spike
Huge bet on sept 18 27 calls
Dollar getting smacked down a bit
That's what idiots get for jail breaking it . Apple is solid as long as you don't go around the software
Just a guess but shorty bout to get run the FAQ over
All IMO
Anyone catch at the open how disconnected SPY was vs SPX on the opening candle..
I think the very real ETF issues are among us - some have been screaming that ETFS were going to a problem at some point..
Looking better is a chit market lol
Took forever to get filled faqers out .43 - tried like hell to get .50
Wondering how my lotto sept 11 - 175 puts are going to look ?
Cost basis .27
Apple taking on Netflix - now that could get really interesting
SPX aug 31 option exp today - 1975 pegging